S&P Biotech SPDR (NY: XBI )
74.19 +0.47 (+0.64%) Official Closing Price Updated: 8:00 PM EDT, Mar 24, 2023 Add to My Watchlist
All News about S&P Biotech SPDR
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
March 10, 2023
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following